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Abstract
Peroxisome proliferator-activated receptor-c (PPARc) has been reported to be involved in the etiology of pathological
features of Alzheimer’s disease (AD). Cannabidiol (CBD), a Cannabis derivative devoid of psychomimetic effects, has
attracted much attention because of its promising neuroprotective properties in rat AD models, even though the
mechanism responsible for such actions remains unknown. This study was aimed at exploring whether CBD effects could be
subordinate to its activity at PPARc, which has been recently indicated as its putative binding site. CBD actions on b-
amyloid-induced neurotoxicity in rat AD models, either in presence or absence of PPAR antagonists were investigated.
Results showed that the blockade of PPARc was able to significantly blunt CBD effects on reactive gliosis and subsequently
on neuronal damage. Moreover, due to its interaction at PPARc, CBD was observed to stimulate hippocampal neurogenesis.
All these findings report the inescapable role of this receptor in mediating CBD actions, here reported.
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Introduction
Despite a significant increase in the understanding of the
pathogenesis of Alzheimer’s disease (AD) over the past two
decades, therapeutic options for treating this condition are still
very disappointing.
Depending on the heterogeneity of pathways that could initiate
and drive sporadic AD, effective treatment for this illness rests on
the ability to develop a multi-targeted approach, as used in current
practice for other multi-factorial disorders [1]. According to this
assumption, both natural and synthetic cannabinoids have been
proposed as novel potential pharmacological tools able to blunt
underlying disease processes, thus ameliorating symptoms and
slowing down illness progression [2,3].
Unfortunately, Cannabis derivatives are therapeutically limited
by their unwanted psychotropic effects. However, one interesting
exception to this is represented by cannabidiol (CBD), the major
constituent of the plant, which lacks any undesired psychomimetic
action. Converging evidence provided over the last years, also by
our group, demonstrated that CBD may account for a significant
reduction of b amyloid (Ab) induced neuronal cell death, due to its
ability to scavenge reactive oxygen species and reduce lipid
peroxidation [4]. That CBD exerts anti-inflammatory properties,
impairing the inducible form of nitric oxide synthase (iNOS) and
interleukin 1b (IL-1b) expression which consequently decreases
their release was also proved in an in vivo model of AD [5].
Moreover, CBD was reported to blunt t hyperphosphorylation in
cultured neurons by reducing phosphorylation of glycogen
synthase kinase 3b (GSK3b), acting as a Wnt/b-catenin pathway
rescuer, although alternative mechanisms may be implicated in
inducing this effect [6]. Indeed, since GSK3b also promotes
amyloid precursor protein (APP) processing, and so increasing Ab
generation [7], the CBD-mediated inhibition of GSK3b is likely to
be effective in reducing the amyloid burden. Moreover, CBD was
also described to protect neurons against glutamate toxicity [8], an
effect occurring independently of the cannabinoid receptor 1
(CB1) signalling [9]. Despite such impressive properties and
promising actions, the precise site at which CBD could exert its
neuroinflammatory and neuroprotective effects is still not fully
elucidated. The recently discovered ability of different cannabi-
noids, including CBD, to display an extra-cannabinoid receptor
binding activity has been highlighted by the observation that these
compounds may go nuclear to exert their activity through the
interaction with peroxisome proliferator-activated receptors
(PPARs) [10]. The PPARs belong to the family of nuclear
hormone receptors and their activity is generally regulated by
steroids and lipid metabolites. At present three different PPAR
isoforms (PPARa, PPARb, also called d, and PPARc) have been
identified [11]; they have been reported to control the expression
of genes related to lipid and glucose homeostasis and inflammatory
responses [12]. A growing body of evidence suggests PPARs as
drug targets for treating several dysmetabolic conditions and
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in the CNS at low levels under physiological condition [13].
However, in some pathological situations, including AD, PPARc
expression, but not other isoforms, was shown to be elevated [14].
These findings suggested that PPARc could play a role in
regulating pathophysiological features of AD and established the
basis for modulation of PPARc activity in the treatment of the
disease.
Therefore the present study was aimed at exploring whether
CBD neuroprotective effects depend upon its activity on PPARs
receptors, particularly on PPARc isoform. To this purpose, the
involvement of PPARs receptors in mediating anti-inflammatory
and neuroprotective effects of CBD both in vitro in primary
cultured astrocytes and in vivo, in a rat model of AD-related
neuroinflammation induced by the intrahippocampal injection of
fibrillar Ab (1–42) peptide was evaluated.
Results
CBD blunted neuroinflammation sustained by astrocytes
through PPARc selective activation in vitro and in vivo
The first set of experiments was aimed at assessing the role of
CBD (10
29–10
27 M) on the release of inflammatory mediators
induced by Ab challenge (1 mg/ml). Treatment with Ab for 24 h
resulted in a significant increase of NO, IL-1b, TNFa, and S100B
release, as determined by Griess reaction and ELISA experiments
(Figure 1). CBD concentration dependently antagonized the
enhanced release of these pro-inflammatory molecules, and
blockade of PPARc with GW9662 (PPARc antagonist, 9 nM)
reversed this effect.
In astrocyte lysates, made 24 h after treatment, the parallel
expression of iNOS, GFAP, and S100B was evaluated. CBD, in a
concentration dependent manner, attenuated the Ab-induced
protein up-regulation and such an effect was related to the
inhibition of NFkB. In fact, in astrocyte lysates prepared 3 h after
treatment, CBD down-regulated the expression of both p50 and
p65. The reduction of reactive gliosis displayed by CBD was to be
considered as the result of a selective PPARc dependent NFkB
inhibition (Figure 2).
Results from hippocampal homogenates, isolated from rats Ab-
injected in the dorsal hippocampus and intraperitoneally admin-
istered with CBD in the presence or absence of MK886 (PPARa
antagonist) and GW9662, demonstrated that Ab induced the up-
regulation of iNOS, GFAP, and S100B towards vehicle injected
rats. CBD blunted Ab effect through a reasonable inhibition of
NFkB, as revealed by the parallel down-regulation of both p50
Figure 1. Effect of CBD on the release of inflammatory mediators by in vitro cultured astrocytes. Ab-challenged astrocytes (1 mg/ml) were
treated with CBD (10
29–10
27 M) in the presence of PPARa (MK886, 3 mM) or PPARc (GW9662, 9 nM) antagonist. 24 h later, NO production was
determined by measuring nitrite (NO2
2) accumulation in the culture medium (A), whereas IL-1b, TNFa, and S100B release was determined by ELISA
experiments (B,C,D). Each bar shows the mean 6 S.E.M. of five separate experiments. ***p,0.001 vs. control; up,0.05, uup,0.01, and uuup,0.001 vs.
Ab-challenged cells.
doi:10.1371/journal.pone.0028668.g001
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calbindin down-regulation. All these observed effects displayed by
CBD were caused by the selective activation of PPARc (Figure 3).
CBD administration inhibited reactive gliosis and rescued
neuronal survival in Ab-injected rat hippocampi through
PPARc activation
In vivo experiments were aimed at assessing the potential
modulating role of CBD on reactive gliosis and neuronal survival
in rat hippocampi. Results from Nissl staining indicated that Ab
injection caused a severe neuronal loss, especially in CA1 area (site
of injection), towards vehicle injected animals, while at the same
time Ab caused a marked astrocytic activation, as demonstrated by
the increased expression of GFAP. According to in vitro results, in
vivo 15 consecutive days administration of CBD (10 mg/kg) almost
completely rescued CA1 pyramidal neurons integrity and this was
accompanied by a massive down-regulation of gliosis entity as
shown by a significant decrease of GFAP immunostaining. Once
animals were treated with PPARc antagonist (GW9662, 10 mg/
kg) CBD neuroprotective functions resulted completely abolished
(Figure 4 A, B).
Moreover, our results indicated that CBD treatment restored
neurogenesis in dentate gyrus of Ab-injected rat hippocampi
through PPARc selective activation.
The DG of rat hippocampi processed for DCX immunofluo-
rescence revealed that Ab treatment markedly reduced the entity
of neurogenesis, as demonstrated by the reduction of DCX-
immunopositive nuclei. CBD treatment was able to counteract
Ab-induced DCX depletion up to stimulate the basal neurogenesis
Figure 2. Effects of CBD on Ab-induced iNOS, GFAP, S100B, and p50/p65 expression in rat astrocytes. Ab-challenged cells (1 mg/ml)
were treated with CBD (10
29–10
27 M) in the presence of PPARa (MK886, 3 mM) or PPARc (GW9662, 9 nM) antagonist. iNOS, GFAP, and S100B
expression was evaluated by Western blot 24 h after treatments. NF-kB activation was evaluated 3 h following treatments by Western blot analysis of
its component p50 and p65. Figure shows results of Western blot analysis of proteins (A) and densitometric analysis of corresponding bands (B).
Results are the mean 6 S.E.M. of four separate experiments. ***p,0.001 vs. control; up,0.5, uu p,0.01, and uuup,0.001 vs. Ab-challenged cells.
doi:10.1371/journal.pone.0028668.g002
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activity was unaffected by PPARa antagonism, whereas its effect
was almost completely abolished by GW9662, the PPARc
antagonist (Figure 4, C).
Discussion
Chronic neuroinflammation implicates protracted activation of
both microglial and astroglial cells, with the consequent sustained
release of pro-inflammatory molecules [15,16], that act in an
autocrine way to self-perpetuate reactive gliosis and in a paracrine
way to kill neighboring neurons, thus expanding the neuropath-
ological damage. Once started, neuroinflammation promotes
neuronal death, powering a vicious cycle responsible for the
progression of the pathology [17]. The possibility of interfering
with this detrimental cycle by molecules which can reduce reactive
gliosis has been proposed as a novel rationale to develop drugs able
to blunt neuronal damage and consequently slow the course of
AD.
Results from the present study prove the selective involvement
of PPARc in the anti-inflammatory and neuroprotective effects of
CBD here observed either in vitro and in vivo. In addition, CBD
significantly promoted neurogenesis in Ab injured rat hippocampi,
much expanding its already wide spectrum of beneficial actions
exerted in AD models, a non negligible effect, due to its capability
to activate PPARc.
CBD was already reported to exert a marked anti-inflammatory
effect through the A2A and 5HT1A receptors [18,19], as well as to
improve brain function [20]. In addition, it has been already
demonstrated that CBD markedly downregulate reactive gliosis by
Figure 3. Effects of CBD on Ab-induced iNOS, GFAP, S100B, calbindin, and p50/p65 expression in rat hippocampi. Results of Western
blot analyses of iNOS, GFAP, S100B, calbindin, and p50/p65 performed on rat hippocampus homogenates (A) and densitometric analysis of
corresponding bands (B). Results are the mean 6 S.E.M. of three separate experiments. *** p,0.001 vs. vehicle inoculated rats; uup,0.01 and
uuu p,0.001 vs. Ab-inoculated rats.
doi:10.1371/journal.pone.0028668.g003
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strongly occurs in Ab neurotoxicity. This activity was linked to its
ability to act as a potent inhibitor of NFkB activation induced by
Ab challenge [21]. The present findings, confirming the formerly
obtained results and extending our knowledge about CBD
pharmacology, indicate that a selective PPARc activation occurs
upstream to CBD-mediated NFkB inhibition. Such activation
appears to be responsible for a large plethora of CBD effects.
Indeed, the interaction of CBD at the PPARc site results in a
profound inhibition of reactive gliosis as showed by the reduction
of both GFAP and S100B protein expression together with a
marked decline of pro-inflammatory molecules and cytokine
release observed in Ab challenged astrocytes.
The in vitro findings were replicated in in vivo experiments, since
once again CBD treatment resulted in a profound inhibition of
astrocytic activation surrounding CA1 area Ab-injected and
induced a rescue of CA1 neuronal viability in comparison to
control.
Along this line, results from hippocampal homogenates fully
matched with in vitro data previously obtained from primary
cultured astrocytes. Also in this case, CBD through the activation
of PPARc provoked a marked reduction of NO, TNFa, and IL-1b
release in association with a parallel decline of GFAP, S100B, and
iNOS protein expression. The observation that in the hippocam-
pus the selective activation of PPARc caused a decrease in p50
and p65 protein expression, further reinforces the importance of
the sequence of events PPARc activation/NFkB inhibition as
responsible for the CBD anti-inflammatory effect. The PPARc
mediated inhibition of S100B induced by CBD represents a crucial
step in interrupting self-perpetuation of the reactive gliosis cycle.
Indeed, the over-release of this astroglial-derived neurotrophin
actively exacerbates the pro-inflammatory cytokine loop fuelled by
Ab stimulation, massively accelerates amyloidogenicity by pro-
moting cleavage of APP to Ab and induces tau protein
hyperphosphorylation, by disrupting the Wnt pathway [22–24].
Notably, both in vivo and in vitro, a selective involvement of
PPARc at the base of the neuroprotective and anti-gliotic effect of
CBD appears peremptory, since a complete loss of any beneficial
pharmacological activity of this phytocannabinoid occurs when it
was co-administered with the PPARc antagonist GW9662.
Neuroprotective effects exerted by PPARc agonists in neuro-
pathological conditions, including Ab induced neuroinflammation
and neurodegeneration have been largely described in the past
years [25]. Besides microglial cells, emerging data indicate
astrocytes and neurons as fundamental cell type targets for the
beneficial role of PPARc ligands [26]. Astrocytes represent the
most abundant glial cells type in the CNS. Once these cells
undergo reactive activation, they produce cytokines and other
molecules involved in inflammatory response, which are thought
to significantly contribute to expand brain damage. Interestingly
astrocytes express the highest level of PPARc in the CNS [27,28],
and accumulating evidence over the last decade indicate that
PPARc agonists may finely regulate their detrimental functions
during a protracted activation exerting a profound anti-inflam-
matory and neuroprotective effects [29].
Such well-defined and highly effective beneficial activity due to
PPARc activation has recently demonstrated to functionally
inactivate NFkB promoters inducing a massive down regulation
of the activation of this transcription factor. Traditional PPARc
agonists like thiazolidinediones were reported to inhibit the
overproduction of NO, IL-6, and TNF-a as well as the increased
expression of the inducible enzymes iNOS and COX2 induced in
LPS-stimulated astrocytic and microglial cultures [30–32]. Taken
together all these findings fully match those concerning the anti-
inflammatory and neuroprotective activities exhibited by CBD in
this study.
AD neuroinflammation is a highly important feature that has
been considered responsible for the progressive worsening of the
disease. Given the tremendous complexity of AD, however, it
appears to be oversimplified reasoning to consider only reactive
astrogliosis and neuronal degeneration as the unique factors at the
basis of the functional decline provoked by the course of the illness.
Neuropathological investigation has provided evidence that in
AD brains progressive neuronal loss is not accompanied by a new
neuronal replacement while alterations in neurogenesis have been
reported to occur [33]. Both aspects are considered to be
important in contributing to the long-term development of
disease. Therefore the disease symptoms could partly be due to
the impaired replacement of new hippocampal neurons from
endogenous neuronal stem cells [34,35], which is believed to
promote learning and memory. Although there were some
controversies over whether neurogenesis is increased or reduced
in the pathogenesis of AD, later studies have confirmed deficient
maturation of new neurons in AD patients [36]. As a result, an
approach to enhance neurogenesis and/or maturation should be
considered potential therapies for AD.
Moreover, activation of PPARc has been reported to promote
neurogenesis and agonists at these receptors regulate neuronal
stem cell proliferation and differentiation as well [37]. In addition
PPARc activation promotes neurite outgrowth in mature neurons,
Figure 4. Effects of CBD on reactive gliosis, neuronal survival,
and neurogenesis in rat hippocampi. A: representative photomi-
crographs of the CA1 area of rat hippocampus showing the results of
immunohistochemical evaluation of GFAP. B: representative photomi-
crographs showing the results of Nissl staining of the whole rat
hippocampus (2X magnification) and the corresponding CA1 region
(10X magnification). C: immunofluorescence photomicrographs show-
ing a particular (10X magnification) of DCX-labeled cells in the dentate
gyrus (DG) of rat hippocampi.
doi:10.1371/journal.pone.0028668.g004
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neuronal networks [38]. According to these observations, results
from the current investigation demonstrate that CBD-mediated
activation of PPARc is associated with a significant neurogenic
activity in the granule cell layer of the hippocampal DG. Results
indicate that CBD markedly counteracts the massive reduction of
neurogenesis in the DG caused by Ab exposure towards control
animals and this effect is consequential, as expected, to a selective
PPARc involvement.
It has been recently asserted that CBD could promote adult
hippocampal neurogenesis by activating CB1 receptors [39]. Such
an assumption was supported by the observation that the CBD
neurogenic effect was lost in CB1 knock-out mice, suggesting that
the pro-neurogenic action of this phytocannabinoid was clearly
dependent on the interaction at the CB1 receptor, which shows a
wide expression over the entire DG, including the neuronal
precursor cells. However, the observation that D9-tetrahydrocan-
nabinol, a preferential agonist at CB1 receptor site, failed in the
same investigation to affect hippocampal neurogenesis, tempers
the notion that CB1 receptor activation and CBD neurogenetic
properties are linked in a straightforward way. Since CBD exhibits
negligible affinity to CB1 receptors and the majority of actions
appears to be cannabinoid receptor independent, it is possible to
assume that the CBD effect on neurogenesis could only involve
CB1 receptor sites indirectly.
In conclusion, results of the present research demonstrate that
CBD may exert protective functions through a PPARc dependent
activation, which leads to a reduction in reactive gliosis and
consequently in neurodegeneration. Moreover, in the current
experimental conditions this phytocannabinoid appears to stimu-
late neurogenesis since it increases DCX immunopositive cell
proliferation rate in rat DG.
Innovative therapeutic approaches which could significantly
improve AD course require new molecules that will be able to have
animpactondifferentpathologicalpathways,which convergeatthe
progressive neurological decline. CBD has shown a capability to
profoundly reduce reactive astrogliosis and to guarantee both direct
and indirect neuronal protection in Ab induced neuroinflamma-
tion/neurodegeration. So far, the lack of understanding of the
precise molecular mechanism involved in CBD pharmacological
actions, has had limited interest and has puzzled investigators.
Currently, findings of the present study throw some light on the
issue, and frame CBD as a new PPARc activator.
Materials and Methods
Ethics Statement
All experiments were performed in accordance with the
National Institutes of Health Guidelines for the Care and Use of
Laboratory Animals (Institute of Laboratory Animal Resources,
1996) and those of the Italian Ministry of Health (D.L. 116/92),
and they were approved by the Institutional Animal Care and Use
Committees (Centro Servizi Veterinari-University of Naples
Federico II; PROT. 012F).
Astrocyte culture
Rat primary astroglial cultures were obtained from newborn
Sprague-Dawley rats (two days old) according to Vairano et al.
[40]. Brains were mechanically processed to obtain single cells that
were seeded in 75 cm
2 flasks at a density of 3610
6 cells/flask with
15 ml of culture medium (DMEM, 10% inactivated FBS, 100 IU/
ml penicillin, 100 mg/ml streptomycin; all from Sigma Aldrich)
and incubated at 37uC in a humidified atmosphere containing 5%
CO2. Astrocytes were mechanically separated from microglia and
oligodendrocytes, and plated onto 10 cm ø Petri dishes at a density
of 1610
6 cells/dish or onto eight chambers polystyrene culture
slides at a density of 3610
4 cells/chamber, depending upon the
experimental procedure. Purity of cell cultures was tested by
immunofluorescence with monoclonal anti-glial fibrillary acidic
protein (GFAP) and only cultures with more than 95% GFAP-
positive cells were employed for the experiments.
Treatments in isolated primary astrocytes
Confluent primary astrocyte cultures were treated with 1 mg/ml
Ab (1–42) (Tocris Bioscience) in the presence or absence of the
following substances: CBD (10
29–10
27 M), MK886 (3 mM), the
selective PPARa antagonist, and GW9662 (9 nM), the selective
PPARc antagonist (all purchased from Tocris Bioscience). The
concentrations of the substances were chosen according to the
results of a series of pilot experiments aimed at identifying the
lowest effective concentration (data not shown). No significant
variation versus control was observed when CBD, MK886, or
GW9662 were given alone (data not shown).
Nitric oxide (NO) measurement
Production of nitric oxide (NO) was determined by measuring
the amount of nitrite (NO2
2) accumulated in supernatants of
primary rat astroglial cells 24 h after treatments and in the
inoculated ipsilateral hippocampi homogenates deriving from in
vivo experiments. A spectrophotometer assay based on the Griess
reaction was used [41]. The absorbance of controls and unknown
samples was measured at 540 nm. The NO2
2 concentration was
thus determined using a standard curve of sodium nitrite (NaNO2)
and referred to 1610
6 cells for the in vitro experiments or expressed
as NO2
2 referred to mg of homogenized hippocampal protein
content for the in vivo experiments.
ELISA
Quantitative determination of Tumor Necrosis Factor alpha
(TNFa), interleukin 1b (IL1b), and S100B was carried out
performing Enzyme Linked-Immuno-Sorbent Assay (ELISA)
assays in vitro and in ex vivo deriving samples from homogenated
hippocampi ipsilateral to the inoculation site; (TNFa and IL b kits
purchased from Invitrogen; S100B kit from BioVendor). In in vitro
experiments, 24 h after treatments, cell culture medium was
collected and ELISA assay was performed according to kit
instruction. Similarly, samples collected by hippocampal homog-
enates deriving from the in vivo experiments, also undergo ELISA.
Western Blot analysis
Twenty-four hours after treatment, harvested astrocytes (1610
6
cells) were washed twice with ice-cold PBS, and collected by
centrifugation at 180 g for 10 min at 4uC. Pellets were
resuspended in 50 ml of ice-cold hypotonic lysis buffer (Tris/HCl
pH 7.5 50 mM; NaCl 150 mM; EDTA 1 mM; Triton X-100 1%)
supplemented with the proper protease inhibitor cocktail (Roche)
and incubated on ice for additional 15 min. Ipsi- lateral
hippocampi to injection site, deriving from in vivo experiments,
were dissected from frozen excised rat brains and lysed with the
same buffer. Cells or hippocampi were then mechanically lysed,
and the total protein extracts were obtained by centrifugation at
13,000 g for 15 min at 4uC. Samples were subjected to SDS-
polyacrylamide gel electrophoresis, and proteins were transferred
onto nitrocellulose membrane and incubated with one of the
following antibodies: anti-GFAP 1:50000; anti-iNOS 1:200; anti-
p50 1:400, anti p65 1:1000, anti-calbindin 1:1000, anti-S100B
1:1000, anti b-actin 1:1000 (all purchased from Abcam). After
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membrane was incubated for 2 h at room temperature with the
proper secondary HRP-conjugated antibodies anti-mouse (1:2000)
or anti-rabbit (1:3000; both purchased from Abcam). Finally, the
membrane was developed by using enhanced chemiluminescence
substrate (ECL from Invitrogen). Bands were revealed through a
Versadoc (Bio-Rad Laboratories) and the corresponded digital
images were analyzed with Quantity One Software (Bio-Rad
Laboratories).
Rats and Surgical Procedures
Adult male Sprague-Dawley rats (300–350 g)wereobtained from
Harlan Italy. They were housed in a pathogen-free barrier facility
under a 12-h light/dark cycle, with ad libitum access to food and
water. Rats (n=40) were anesthetized i.p. with pentobarbital
(60 mg/kg). They were then placed in a stereotaxic frame and
inoculated with human Ab (1–42) (Tocris Cookson) into the CA1
area (AP 23.3, ML 21.2, DV 22.6) The peptide was dissolved in
artificial cerebrospinal fluid to the concentration of 10 mg/ml, and
3 mlwasinjected usingamicrodialysispump,keepingthe flowtothe
constant value of 0.5 ml/min. Control rats (n=8) were treated
according to the same procedure, and they were inoculated with an
equivalent volume of artificial cerebrospinal fluid.
In Vivo Treatments
After full recovery from stereotaxic surgery, depending upon the
experimental protocol design, rats were i.p. administered for 15
days with: CBD 10 mg/kg, MK886 10 mg/kg, and GW9662
1 mg/kg. All coumpounds were dissolved in PEG/Tween80/
saline (Sigma Aldrich), 5:5:90. Control rats were i.p. given an
equivalent volume of the proper vehicle. All drug solutions were
freshly prepared on the day of the experiment. The drug
concentrations were chosen according to their IC50, and on the
basis of the results of our preliminary experiments. Rats to be
subjected to immunoblotting experiments underwent deep anaes-
thesia and sacrificed by decapitation. Their brains were extracted
and ipsilateral hippocampi to injection site were dissected and
frozen in liquid N2 before the tissue lysis for immunoblot analysis
and/or ELISA assay. Rats to be subjected to morphological
analysis were sacrificed through transcardiac perfusion with
paraformaldehyde 4%. The extracted brains were post-fixed
overnight with the same fixative, protected with 30% sucrose, and
frozen using 2-methylbutane.
Immunohistochemistry
Immunohistochemistry analyses were performed on hippocam-
pal coronal sections adjacent to the site of the injection, obtained
from both control and treated rats. Free-floating sections were
treated with PBS containing 15 mM NaN3, 10% albumin, and
0.25% Triton X-100, and then they were incubated at 4uCi na
damp chamber by continuous shaking with mouse anti-GFAP
antibody (1:400, Sigma Aldrich). After two overnight incubation,
sections were treated with the biotinylated secondary antibody
(1:200; Vector Laboratories) and with the preformed avidin-
biotinylated peroxidase complex (VECTASTAIN ABC kit; Vector
Laboratories), and the reaction was revealed by 3,3-diaminoben-
zidine tetrahydrochloride (Sigma Aldrich). Sections were mounted
upon gelatin-coated slides before coverslipping with a non-
aqueous medium.
Immmunofluorescence
In the same experimental conditions above described, immu-
nofluorescence analyses were performed on hippocampal coronal
sections adjacent to dentate gyrus (DG). Briefly, slices derived from
both control and treated rats were blocked in 10% albumin bovine
serum 0.1% Triton-PBS solution for 90 min and subsequently
incubated for 1 h with a 10% albumin bovine serum 0.1% Triton-
PBS solution of anti-doublecortin (DCX) antibody (dil. 1:250 v/v).
DCX antibody was purchased from Cell Signaling. Sections were
incubated for 1 h in the dark with the proper secondary antibody:
Tetramethyl Rhodamine Isothiocyanate (TRITC) conjugated
anti-rabbit 1:100 (both from Abcam). Pictures were taken using
a camera (Nikon DIGITAL SIGHT DS-U1) connected with a
microscope (Nikon ECLIPSE 80i by Nikon Instruments Europe)
provided of the proper fluorescent filters. Slides were thus
analyzed with a microscope (Nikon ECLIPSE 80i by Nikon
Instruments Europe), and images were captured at 10X
magnification by a high-resolution digital camera (Nikon DIGI-
TAL SIGHT DS-U1).
Statistical Analysis
Results were expressed as mean 6 S.E.M. of experiments.
Statistical analysis was performed using parametric one-way
analysis of variance, and multiple comparisons were performed
by Bonferroni’s test. Values of p,0.05 were considered significant.
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